Cargando…

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

BACKGROUND: Hereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iaboni, Aled, Kanani, Amin, Lacuesta, Gina, Song, Christine, Kan, Manstein, Betschel, Stephen D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306280/ https://www.ncbi.nlm.nih.gov/pubmed/34301329 http://dx.doi.org/10.1186/s13223-021-00579-6

Ejemplares similares

Lanadelumab for hereditary angioedema
Publicado: (2022)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories
por: Charest-Morin, Xavier, et al.
Publicado: (2018)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Urticaria and angioedema
por: Kanani, Amin, et al.
Publicado: (2018)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Malignancy and immune disorders in patients with hereditary angioedema
por: Stepaniuk, Peter, et al.
Publicado: (2021)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series
por: Iaboni, Aled, et al.
Publicado: (2022)

Hereditary angioedema restricted to the digestive tract
por: Sochal, Marcin, et al.
Publicado: (2018)

Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema
por: Kutlu, Ali, et al.
Publicado: (2016)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

A challenging diagnosis: hereditary angioedema presenting during pregnancy
por: Chair, Irene, et al.
Publicado: (2022)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Perioperative management of emergency caesarean section in type I hereditary angioedema
por: Srinivasan, Gnanasekaran, et al.
Publicado: (2022)

Characterizing telemedicine use in clinical immunology and allergy in Canada before the COVID-19 pandemic
por: Lee, Erika Yue, et al.
Publicado: (2021)

Evaluation of retinal microvascular perfusion in hereditary angioedema: a case-control study
por: Triggianese, Paola, et al.
Publicado: (2020)

Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36
por: Jindal, Nina Lakhani, et al.
Publicado: (2017)

Urticaria and angioedema
por: Kanani, Amin, et al.
Publicado: (2011)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

The role of C1 inhibitor and complement as acute phase reactants: are we missing the diagnosis of hereditary angioedema?
por: Stepaniuk, Peter, et al.
Publicado: (2021)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
por: Bowen, Tom, et al.
Publicado: (2010)

Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria
por: Stepaniuk, Peter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p14qjbfl74lhftuu74fa0ehhkl